1. Genetic tests
  2. Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil (5-FU) toxicity) - Pharmacogenetics

Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil (5-FU) toxicity) - Pharmacogenetics

Genetic test Export to PDF
Full name:
Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil (5-FU) toxicity) - Pharmacogenetics
Description:

DPYD genotyping (4 hot spot variants ( c.1679T>G (DPYD*13), c.1905+1G>A (IVS14+1G>A - DPYD*2A) et c.2846A>T(D949V, rs67376798) and c.1236G>A (HapB3, rs56038477) ).
Test type:
Clinical
Test specialty:
Molecular Genetics
Test purpose:
Drug Response
Specimen:
Peripheral (whole) blood on EDTA
Method category:
Mutation screening
Method technique:
PCR based technique
Laboratory:
Centre de Génétique Humaine - CHU Sart-Tilman
RIZIV code:
565390-565401
EQA:
  • 2019 DPYD (Pharmacogenetics PGX3) CAP-College of American Pathologist
  • 2022 pharmacogenetic panel EMQN
Accreditation (ISO 15189):
2022-02-24 / 2026-02-23
Turnaround time (maximum):
5 days
Document(s):
Created:
25 Jul 2019 - 17:27
Changed:
16 Jan 2024 - 13:26
URL:
https://www.chuliege.be/jcms/c_6963510/fr/etude-du-gene-dpyd-toxicite-du-5-fu